Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 268 Neoplasm Metastasis 36 Neoplasms 21 Ovarian Neoplasms 17 Advanced Breast Cancer 16 Endometrial Neoplasms 11 Prostatic Neoplasms 9 Carcinoma, Non-Small-Cell Lung 9 Hereditary Sensory and Autonomic Neuropathies 8 Triple Negative Breast Neoplasms 5 Multiple Endocrine Neoplasia Type 1 5 Breast Diseases 5 Breast Cancer Metastatic 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Neoplasms by Site 4 Colorectal Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Liposarcoma 2 Hyperglycemia 2 HER2-positive Breast Cancer 2

Interventions

Lenalidomide 4 Dexamethasone 4 Bortezomib 4 Cyclophosphamide 3 Cisplatin 3 Carboplatin 3 pomalidomide 2 pembrolizumab 2 durvalumab 2 capivasertib 2 Radiosurgery 2 Paclitaxel 2 Nivolumab 2 Gemcitabine 2 Bevacizumab 2 Anthropogenic Effects 2 venetoclax 1 vandetanib 1 umbralisib 1 ublituximab 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tremelimumab 1 tivozanib 1 ricolinostat 1 pazopanib 1 niraparib 1 nilotinib 1 lutetium Lu 177 dotatate 1 liposomal doxorubicin 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06635447 2026-01-13

CAPItrue

AstraZeneca

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡